



Clinical trial results:

A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/AS01

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2016-001718-31 |
| Trial protocol | GB |
| Global end of trial date | 27 June 2019 |

Results information

| | |
|--------------------------------|-------------------|
| Result version number | v1 (current) |
| This version publication date | 17 September 2020 |
| First version publication date | 17 September 2020 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | VAC063 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02927145 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | University of Oxford, CTRG |
| Sponsor organisation address | Old Road, Oxford, United Kingdom, OX3 7LE |
| Public contact | Angela Minasian, University of Oxford, 0044 01865611425, angela.minassian@ndm.ox.ac.uk |
| Scientific contact | Angela Minasian, University of Oxford, 0044 01865611425, angela.minassian@ndm.ox.ac.uk |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 27 June 2019 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 27 June 2019 |
| Global end of trial reached? | Yes |
| Global end of trial date | 27 June 2019 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess the safety of the RH5.1/AS01 vaccine in healthy volunteers at different doses.

To establish whether the RH5.1/AS01 vaccine can demonstrate a reduced parasite multiplication rate in vaccinated subjects compared to infectivity controls in a blood-stage controlled human malaria infection model.

Protection of trial subjects:

- Volunteers given at least 24 hours to read VIS before being seen and then given plenty of opportunity to ask questions prior to agreeing to take part in a study.
- Volunteers for Groups 5-9 asked to complete a questionnaire testing their understanding of the trial as part of the consent process to ensure that individuals understand the trial sufficiently to give informed consent.
- Screening visit including full medical history, physical examination and baseline blood tests to ensure volunteers are healthy prior to enrolment.
- Vaccination carried out in clinical environment with staff trained in resuscitation in case of allergic reaction.
- Safety review prior to dose escalation (LSM) - Volunteers seen within 1 - 3 days of vaccination for safety review and provided with 24/7 contact number for trial clinician and emergency contact card for the department.
- Inclusion of AE related safety stopping/holding rules at both a group and individual level in the protocol.
- Volunteers given emergency contact card detailing that they have been infected with malaria.
- Volunteers seen twice daily once blood stage malaria is possible with twice daily malaria films and PCR
- Malaria treated promptly when diagnosed with highly efficacious medication and at least half of doses directly observed.
- Volunteers provided with symptomatic treatment (antipyretic/analgesic and antiemetic) in case of malaria symptoms.
- Volunteers who remained undiagnosed with malaria at Day 21 given a treatment course of anti-malarials.
- Volunteers followed up until at least 2 consecutive negative blood films seen or two consecutive qPCR results with substantial reduction in genome copies/mL.
- Volunteers observed for 1 hour after vaccination to monitor for any immediate adverse effects.
- Total blood volume taken during study kept to volume that should not compromise healthy volunteers.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------------|
| Actual start date of recruitment | 01 September 2016 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Scientific research |
| Long term follow-up duration | 2 Years |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United Kingdom: 90 |
| Worldwide total number of subjects | 90 |
| EEA total number of subjects | 90 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 90 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Volunteers were recruited by use of advertisements, formally approved by the ethics committee, distributed or posted in public places (including newspapers, social media, stalls at fairs and public transport) or via email distribution, including to individuals who have registered an interest in taking part in clinical trials at the study sites.

Pre-assignment

Screening details:

Inclusion / Exclusion criteria
Informed Consent Questionnaire
Informed Consent
Medical History
Physical Examination
Urinalysis
Electrocardiogram (Groups 5, 6, 9)
beta-HCG urine (women only)
Review contraindications
Physical Observations
HBV, HCV, HIV
Haematology
Biochemistry

Period 1

| | |
|------------------------------|-----------------------------|
| Period 1 title | Phase I & IIa |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--------------------|
| Are arms mutually exclusive? | No |
| Arm title | Group 1 - Phase 1a |

Arm description:

3 vaccinations (Days 0/28/56) of 2µg RH5.1/0.5 mL AS01 intramuscularly

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

2µg RH5.1 in 0.5mL AS01

| | |
|------------------|--------------------|
| Arm title | Group 2 - Phase 1a |
|------------------|--------------------|

Arm description:

3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

10µg RH5.1 in 0.5mL AS01

| | |
|---|--------------------------|
| Arm title | Group 3 - Phase 1a |
| Arm description: 2 vaccinations (Days 0/28) 50µg RH5.1 in 0.5mL AS01 followed by a third vaccination (Day 182) of 10µg RH5.1 in 0.5mL AS01. | |
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: 50µg RH5.1 in 0.5mL AS01 | |
| Arm title | Group 4 - Phase 1a |
| Arm description: 3 vaccinations (Days 0/28/56) of 50µg RH5.1 in 0.5mL AS01 intramuscularly | |
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: 50µg RH5.1 in 0.5mL AS01 | |
| Arm title | Group 5 - Phase 2a |
| Arm description: 3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly, followed by primary CHMI 2 weeks post 3rd vaccination. | |
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: 10µg RH5.1 in 0.5mL AS01 | |
| Arm title | Group 6 - Phase 2a |
| Arm description: Primary CHMI controls (for primary CHMI in Group 5 and 7) | |
| Arm type | CHMI controls |
| No investigational medicinal product assigned in this arm | |
| Arm title | Group 7 - Phase 2a |
| Arm description: Subset of Group 5. 4 vaccinations (Days 0/28/56/~4 months after 3rd vaccination) of 10µg RH5.1 in 0.5mL AS01. Primary CHMI 2 weeks post 3rd vaccination. Secondary CHMI 1-2 weeks post 4th vaccination. | |
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:
10µg RH5.1 in 0.5mL AS01

| | |
|--|--------------------|
| Arm title | Group 8 - Phase 2a |
| Arm description: Subset of Group 6 undergoing secondary CHMI. Controls for secondary CHMI in Group 7. | |
| Arm type | CHMI controls |
| No investigational medicinal product assigned in this arm | |
| Arm title | Group 9 - Phase 2a |
| Arm description: Primary CHMI controls (for secondary CHMI in Group 7 and 8) | |
| Arm type | CHMI controls |
| No investigational medicinal product assigned in this arm | |

| Number of subjects in period 1 | Group 1 - Phase 1a | Group 2 - Phase 1a | Group 3 - Phase 1a |
|--|--------------------|--------------------|--------------------|
| Started | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 |
| Consent withdrawn by subject | - | - | - |
| Physician decision | - | - | - |
| Pregnancy | - | - | - |
| Back-up volunteers for CHMI (not required) | - | - | - |

| Number of subjects in period 1 | Group 4 - Phase 1a | Group 5 - Phase 2a | Group 6 - Phase 2a |
|--|--------------------|--------------------|--------------------|
| Started | 14 | 17 | 17 |
| Completed | 11 | 17 | 14 |
| Not completed | 3 | 0 | 3 |
| Consent withdrawn by subject | 2 | - | 1 |
| Physician decision | 1 | - | - |
| Pregnancy | - | - | - |
| Back-up volunteers for CHMI (not required) | - | - | 2 |

| Number of subjects in period 1 | Group 7 - Phase 2a | Group 8 - Phase 2a | Group 9 - Phase 2a |
|---------------------------------------|--------------------|--------------------|--------------------|
| Started | 9 | 8 | 6 |
| Completed | 8 | 8 | 4 |
| Not completed | 1 | 0 | 2 |
| Consent withdrawn by subject | - | - | 2 |
| Physician decision | - | - | - |
| Pregnancy | 1 | - | - |

| | | | |
|--|---|---|---|
| Back-up volunteers for CHMI (not required) | - | - | - |
|--|---|---|---|

Period 2

| | |
|------------------------------|------------------------------|
| Period 2 title | Optional long-term follow-up |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--------------------|
| Are arms mutually exclusive? | No |
| Arm title | Group 1 - Phase 1a |

Arm description:

3 vaccinations (Days 0/28/56) of 2µg RH5.1/0.5 mL AS01 intramuscularly. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

2µg RH5.1 in 0.5mL AS01

| | |
|------------------|--------------------|
| Arm title | Group 2 - Phase 1a |
|------------------|--------------------|

Arm description:

3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

10µg RH5.1 in 0.5mL AS01

| | |
|------------------|--------------------|
| Arm title | Group 3 - Phase 1a |
|------------------|--------------------|

Arm description:

2 vaccinations (Days 0/28) 50µg RH5.1 in 0.5mL AS01 followed by a third vaccination (Day 182) of 10µg RH5.1 in 0.5mL AS01. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|--------------------------|
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: 50µg RH5.1 in 0.5mL AS01 | |
| Arm title | Group 4 - Phase 1a |

Arm description:

3 vaccinations (Days 0/28/56) of 50µg RH5.1 in 0.5mL AS01 intramuscularly

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: 50µg RH5.1 in 0.5mL AS01 | |
| Arm title | Group 5 - Phase 2a |

Arm description:

3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly, followed by primary CHMI 2 weeks post 3rd vaccination. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: 10µg RH5.1 in 0.5mL AS01 | |
| Arm title | Group 7 - Phase 2a |

Arm description:

Subset of Group 5 . 4 vaccinations (Days 0/28/56/~4 months after 3rd vaccination) of 10µg RH5.1 in 0.5mL AS01. Primary CHMI 2 weeks post 3rd vaccination. Secondary CHMI 1-2 weeks post 4th vaccination.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | RH5.1 with adjuvant AS01 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: 10µg RH5.1 in 0.5mL AS01 | |

| Number of subjects in period 2 | Group 1 - Phase 1a | Group 2 - Phase 1a | Group 3 - Phase 1a |
|---------------------------------------|--------------------|--------------------|--------------------|
| Started | 9 | 10 | 7 |
| Completed | 9 | 10 | 7 |

| Number of subjects in period 2 | Group 4 - Phase 1a | Group 5 - Phase 2a | Group 7 - Phase 2a |
|---------------------------------------|--------------------|--------------------|--------------------|
| Started | 4 | 3 | 6 |
| Completed | 4 | 3 | 6 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Phase I & IIa |
|-----------------------|---------------|

Reporting group description: -

| Reporting group values | Phase I & IIa | Total | |
|---|---------------|-------|--|
| Number of subjects | 90 | 90 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 90 | 90 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 56 | 56 | |
| Male | 34 | 34 | |

End points

End points reporting groups

| | |
|---|--------------------|
| Reporting group title | Group 1 - Phase 1a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 2µg RH5.1/0.5 mL AS01 intramuscularly | |
| Reporting group title | Group 2 - Phase 1a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly | |
| Reporting group title | Group 3 - Phase 1a |
| Reporting group description: 2 vaccinations (Days 0/28) 50µg RH5.1 in 0.5mL AS01 followed by a third vaccination (Day 182) of 10µg RH5.1 in 0.5mL AS01. | |
| Reporting group title | Group 4 - Phase 1a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 50µg RH5.1 in 0.5mL AS01 intramuscularly | |
| Reporting group title | Group 5 - Phase 2a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly, followed by primary CHMI 2 weeks post 3rd vaccination. | |
| Reporting group title | Group 6 - Phase 2a |
| Reporting group description: Primary CHMI controls (for primary CHMI in Group 5 and 7) | |
| Reporting group title | Group 7 - Phase 2a |
| Reporting group description: Subset of Group 5. 4 vaccinations (Days 0/28/56/~4 months after 3rd vaccination) of 10µg RH5.1 in 0.5mL AS01. Primary CHMI 2 weeks post 3rd vaccination. Secondary CHMI 1-2 weeks post 4th vaccination. | |
| Reporting group title | Group 8 - Phase 2a |
| Reporting group description: Subset of Group 6 undergoing secondary CHMI. Controls for secondary CHMI in Group 7. | |
| Reporting group title | Group 9 - Phase 2a |
| Reporting group description: Primary CHMI controls (for secondary CHMI in Group 7 and 8) | |
| Reporting group title | Group 1 - Phase 1a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 2µg RH5.1/0.5 mL AS01 intramuscularly. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination. | |
| Reporting group title | Group 2 - Phase 1a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination. | |
| Reporting group title | Group 3 - Phase 1a |
| Reporting group description: 2 vaccinations (Days 0/28) 50µg RH5.1 in 0.5mL AS01 followed by a third vaccination (Day 182) of 10µg RH5.1 in 0.5mL AS01. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination. | |
| Reporting group title | Group 4 - Phase 1a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 50µg RH5.1 in 0.5mL AS01 intramuscularly | |
| Reporting group title | Group 5 - Phase 2a |
| Reporting group description: 3 vaccinations (Days 0/28/56) of 10µg RH5.1 in 0.5mL AS01 intramuscularly, followed by primary CHMI | |

2 weeks post 3rd vaccination. Optional long term follow-up at approximately 1.5-2.5 years after 3rd vaccination.

| | |
|-----------------------|--------------------|
| Reporting group title | Group 7 - Phase 2a |
|-----------------------|--------------------|

Reporting group description:

Subset of Group 5 . 4 vaccinations (Days 0/28/56/~4 months after 3rd vaccination) of 10µg RH5.1 in 0.5mL AS01. Primary CHMI 2 weeks post 3rd vaccination. Secondary CHMI 1-2 weeks post 4th vaccination.

Primary: Efficacy of the RH5.1/AS01 vaccine as assessed by a reduction in the PCR-derived parasite multiplication rate (PMR) in vaccinated subjects compared to infectivity controls

| | |
|-----------------|---|
| End point title | Efficacy of the RH5.1/AS01 vaccine as assessed by a reduction in the PCR-derived parasite multiplication rate (PMR) in vaccinated subjects compared to infectivity controls ^{[1][2]} |
|-----------------|---|

End point description:

Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

8 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| End point values | Group 6 - Phase 2a | Group 7 - Phase 2a | Group 8 - Phase 2a | Group 9 - Phase 2a |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 9 | 8 | 4 |
| Units: no of participants | 14 | 9 | 8 | 4 |

Statistical analyses

No statistical analyses for this end point

Primary: Safety of RH5.1/AS01 in healthy malaria-naïve adults in the UK assed by actively and passively collected data on adverse events.

| | |
|-----------------|---|
| End point title | Safety of RH5.1/AS01 in healthy malaria-naïve adults in the UK assed by actively and passively collected data on adverse events. ^[3] |
|-----------------|---|

End point description:

Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Main study: 8 months.

For subset of subjects: up to 2.5 years (optional long-term follow-up).

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| End point values | Group 1 - Phase 1a | Group 2 - Phase 1a | Group 3 - Phase 1a | Group 4 - Phase 1a |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 12 | 12 | 11 |
| Units: Percentage | 12 | 12 | 12 | 11 |

| End point values | Group 1 - Phase 1a | Group 2 - Phase 1a | Group 3 - Phase 1a | Group 4 - Phase 1a |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 9 | 10 | 7 | 4 |
| Units: Percentage | 9 | 10 | 7 | 4 |

| End point values | Group 5 - Phase 2a | Group 7 - Phase 2a | Group 5 - Phase 2a | Group 6 - Phase 2a |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 6 | 17 | 14 |
| Units: Percentage | 3 | 6 | 17 | 14 |

| End point values | Group 7 - Phase 2a | Group 8 - Phase 2a | Group 9 - Phase 2a | |
|-----------------------------|--------------------|--------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 9 | 8 | 4 | |
| Units: Percentage | 9 | 8 | 4 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Humoral and cellular immunogenicity of RH5.1/AS01 when administered to healthy volunteers at different doses.

| | |
|-----------------|--|
| End point title | Humoral and cellular immunogenicity of RH5.1/AS01 when administered to healthy volunteers at different doses. ^[4] |
|-----------------|--|

End point description:

Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

8 months

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| End point values | Group 1 - Phase 1a | Group 2 - Phase 1a | Group 3 - Phase 1a | Group 4 - Phase 1a |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 12 | 12 | 11 |
| Units: n/a (multiple units) | | | | |
| number (not applicable) | 12 | 12 | 12 | 11 |

| End point values | Group 5 - Phase 2a | Group 7 - Phase 2a | | |
|-----------------------------|--------------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 9 | | |
| Units: n/a (multiple units) | | | | |
| number (not applicable) | 17 | 9 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Immunological readouts for association with a reduced parasite multiplication rate.

| | |
|-----------------|--|
| End point title | Immunological readouts for association with a reduced parasite multiplication rate. ^[5] |
|-----------------|--|

End point description:

Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

8 months

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| End point values | Group 5 - Phase 2a | Group 6 - Phase 2a | Group 7 - Phase 2a | Group 8 - Phase 2a |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 17 | 14 | 9 | 8 |
| Units: n/a (multiple units) | | | | |
| number (not applicable) | 17 | 14 | 9 | 8 |

| End point values | Group 9 - Phase 2a | | | |
|-----------------------------|--------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 4 | | | |
| Units: n/a (multiple units) | | | | |
| number (not applicable) | 4 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Durability of any reduction in parasite multiplication rate (PMR) in vaccinated subjects in a second CHMI, ~4 months after the primary CHMI, compared to unvaccinated controls receiving a second challenge and newly recruited malaria-naïve primary controls

| | |
|-----------------|---|
| End point title | Durability of any reduction in parasite multiplication rate (PMR) in vaccinated subjects in a second CHMI, ~4 months after the primary CHMI, compared to unvaccinated controls receiving a second challenge and newly recruited malaria-naïve primary controls ^[6] |
|-----------------|---|

End point description:

Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

12 months

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Due to the confidential nature of this data, we have not provided this analysis at this time. The scientific paper can be uploaded following publication, if required.

| End point values | Group 5 - Phase 2a | Group 6 - Phase 2a | Group 7 - Phase 2a | Group 8 - Phase 2a |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 17 | 14 | 9 | 8 |
| Units: no of participants | 17 | 14 | 9 | 8 |

| End point values | Group 9 - Phase 2a | | | |
|-----------------------------|--------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 4 | | | |
| Units: no of participants | 4 | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Data on solicited adverse events were collected for 7 days after vaccinated and unsolicited adverse events for 28 days post-vaccination.

Data on serious adverse events and adverse events of special interest were collected for the study duration.

Adverse event reporting additional description:

Following each vaccination, volunteers completed an electronic diary card for 28 days with adverse event data. Solicited AEs, collected for 7 days, included local AEs (pain, erythema, warmth, swelling and itching) and systemic AEs (headache, malaise, myalgia, arthralgia, feverishness, nausea, fatigue, and measured fever

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 22.0 |

Reporting groups

| | |
|--------------------------------|--------------------|
| Reporting group title | Group 1 - Phase 1a |
| Reporting group description: - | |
| Reporting group title | Group 2 - Phase 1a |
| Reporting group description: - | |
| Reporting group title | Group 3 - Phase 1a |
| Reporting group description: - | |
| Reporting group title | Group 4 - Phase 1a |
| Reporting group description: - | |
| Reporting group title | Group 5 - Phase 2a |
| Reporting group description: - | |
| Reporting group title | Group 7 - Phase 2a |
| Reporting group description: - | |

| Serious adverse events | Group 1 - Phase 1a | Group 2 - Phase 1a | Group 3 - Phase 1a |
|---|--------------------|--------------------|--------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Surgical and medical procedures | | | |
| Tonsillectomy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Pregnancy | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Group 4 - Phase 1a | Group 5 - Phase 2a | Group 7 - Phase 2a |
|---|--------------------|--------------------|--------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 17 (5.88%) | 1 / 9 (11.11%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Surgical and medical procedures | | | |
| Tonsillectomy | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 17 (5.88%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Pregnancy | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 17 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 17 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 1 %

| Non-serious adverse events | Group 1 - Phase 1a | Group 2 - Phase 1a | Group 3 - Phase 1a |
|---|--------------------|--------------------|--------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 12 (8.33%) | 1 / 12 (8.33%) |

| | | | |
|--|--|----------------|----------------|
| General disorders and administration site conditions | | | |
| Local reaction | Additional description: Reaction at injection site | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 12 (8.33%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Chills | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Group 4 - Phase 1a | Group 5 - Phase 2a | Group 7 - Phase 2a |
|---|--|--------------------|--------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 5 / 17 (29.41%) | 0 / 9 (0.00%) |
| General disorders and administration site conditions | | | |
| Local reaction | Additional description: Reaction at injection site | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 1 / 17 (5.88%) | 0 / 9 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 4 / 17 (23.53%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|--|
| 15 September 2016 | Addition of information regarding the use of the informed consent questionnaire. Correction of schedule of attendances table/blood volumes. Addition of wording to clarify that stated vaccine and adjuvant doses are nominal and may vary slightly due to dilution, mixing and administration techniques. Clarification added regarding ECG as part of screening procedures for Group 5-6. Change in wording of exclusion criterion regarding prior receipt of an investigational malaria vaccine. "History of splenectomy" removed as a separate exclusion criterion. |
| 29 May 2017 | Selection of dose of RH5.1/AS01 (10 µg) for Group 5 in the Phase IIa study. Guy's and St. Thomas' NIHR CRF to continue as a recruitment and vaccination site for the Phase IIa study. Removal of Cardiovascular Risk Score and checking of cholesterol levels from the protocol. Correction of blood volumes in schedule of attendances. Clarification of vaccination of 2 back-up volunteers in Group 5. Clarification of challenge at 2 weeks post final vaccination. Blinding of all Investigators (except the Principal Laboratory Investigator) to the malaria qPCR results during the post-challenge phase. |
| 11 September 2017 | Modification of bleed schedule for Groups 5 and 6. Correction/clarifications to footer of schedule of attendances tables. |
| 23 November 2017 | Addition of conflicts of interest statements of Investigators. Correction of minor typographical errors in the bleeding schedule tables. |
| 23 January 2018 | Addition of 3 new groups to assess the durability of the vaccine-induced reduction in PMR (Group 7 = Phase IIa malaria-exposed vaccinees; Group 8 = Phase IIa malaria-exposed controls; Group 9 = newly recruited malaria-naïve controls). Removal of microscopy as a diagnostic tool in the second homologous CHMI, and adjustment of the qPCR diagnostic criteria for commencing anti-malarials. Addition of 2 new exclusion criteria (Groups 5-9): G6PD deficiency and abnormal haemoglobinopathy screen. Clarification of 2 exclusion criteria (relating to Hepatitis C serology and contraindications relating to use of malarone and riamet). |
| 07 February 2018 | Clarification of scientific rationale for re-challenge of healthy volunteers. |
| 10 October 2018 | Addition of last visit for all vaccinated volunteers (Groups 1-4, 5 and 7) to assess durability of immune responses 1-2.5 years since their final vaccination. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported